B. Riley Wealth Advisors Inc. Cuts Stock Holdings in iShares Biotechnology ETF (NASDAQ:IBB)

B. Riley Wealth Advisors Inc. lessened its holdings in iShares Biotechnology ETF (NASDAQ:IBBFree Report) by 42.1% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 6,783 shares of the financial services provider’s stock after selling 4,939 shares during the period. B. Riley Wealth Advisors Inc.’s holdings in iShares Biotechnology ETF were worth $975,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IBB. BNP Paribas Financial Markets grew its stake in shares of iShares Biotechnology ETF by 29.3% during the third quarter. BNP Paribas Financial Markets now owns 2,380,229 shares of the financial services provider’s stock worth $346,561,000 after acquiring an additional 538,899 shares during the last quarter. Commerce Bank boosted its stake in shares of iShares Biotechnology ETF by 1.8% during the 3rd quarter. Commerce Bank now owns 743,366 shares of the financial services provider’s stock worth $108,234,000 after acquiring an additional 12,921 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund grew its holdings in iShares Biotechnology ETF by 32.9% in the third quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 663,000 shares of the financial services provider’s stock valued at $96,533,000 after purchasing an additional 164,000 shares during the period. Main Management ETF Advisors LLC raised its position in iShares Biotechnology ETF by 2.5% during the third quarter. Main Management ETF Advisors LLC now owns 593,370 shares of the financial services provider’s stock worth $86,395,000 after acquiring an additional 14,535 shares during the period. Finally, Raymond James Financial Services Advisors Inc. lifted its stake in iShares Biotechnology ETF by 24.6% in the 2nd quarter. Raymond James Financial Services Advisors Inc. now owns 217,047 shares of the financial services provider’s stock valued at $29,792,000 after buying an additional 42,822 shares in the last quarter. 62.45% of the stock is currently owned by institutional investors.

iShares Biotechnology ETF Trading Up 0.3 %

Shares of NASDAQ IBB opened at $137.66 on Wednesday. The firm has a 50-day simple moving average of $141.74 and a 200-day simple moving average of $142.40. iShares Biotechnology ETF has a 52 week low of $123.60 and a 52 week high of $150.57.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a dividend, which will be paid on Friday, December 20th. Stockholders of record on Tuesday, December 17th will be issued a dividend of $0.0624 per share. The ex-dividend date is Tuesday, December 17th.

About iShares Biotechnology ETF

(Free Report)

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Featured Articles

Institutional Ownership by Quarter for iShares Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.